Longeveron (LGVN)

Company Profile

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product ("Lomecel-B"), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

Company profile

Ticker

LGVN

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

LONGEVERON LLC

SEC CIK

0001721484

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

472174146

LGVN stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

27 Jan 23

8-K

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

14 Nov 22

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

14 Nov 22

8-K

Departure of Directors or Certain Officers

3 Nov 22

8-K

Regulation FD Disclosure

12 Aug 22

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

12 Aug 22

8-K

Submission of Matters to a Vote of Security Holders

27 Jun 22

8-K

Departure of Directors or Certain Officers

7 Jun 22

Transcripts

View all

LGVN

Earnings call transcript

2022 Q3

14 Nov 22

LGVN

Earnings call transcript

2022 Q2

14 Aug 22

LGVN

Earnings call transcript

2022 Q1

17 May 22

LGVN

Earnings call transcript

2021 Q4

11 Mar 22

LGVN

Earnings call transcript

2021 Q3

12 Nov 21

LGVN

Earnings call transcript

2021 Q2

14 Aug 21

LGVN

Earnings call transcript

2021 Q1

14 May 21

LGVN

Earnings call transcript

2020 Q4

30 Mar 21

Latest ownership filings

View all

Financial summary

Financial statements Chart LGVN financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	13.57 mm	13.57 mm	13.57 mm	13.57 mm	13.57 mm	13.57 mm
Cash burn (monthly)	2.22 mm	(no burn)	1.73 mm	1.40 mm	1.41 mm	1.08 mm
Cash used (since last report)	8.92 mm	n/a	6.96 mm	5.64 mm	5.68 mm	4.34 mm
Cash remaining	4.66 mm	n/a	6.62 mm	7.93 mm	7.90 mm	9.23 mm
Runway (months of cash)	2.1	n/a	3.8	5.7	5.6	8.6

Beta Read what these cash burn values mean

Financial data from Longeveron earnings reports.

Institutional ownership, Q2 2022

LGVN institutional ownership history Ownership history

6.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	14	15	-6.7%
Opened positions	6	5	+20.0%
Closed positions	7	10	-30.0%
Increased positions	4	4	–
Reduced positions	2	2	–

13F shares	Current	Prev Q	Change
Total value	2.24 mm	545.92 mm	-99.6%
Total shares	378.16 k	78.42 mm	-99.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vanguard	173.67 k	$1.03 mm	+49.9%
BLK Blackrock	110.00 k	$652.00 k	+32.5%
Geode Capital Management	35.72 k	$211.00 k	+5.3%
STT State Street	14.80 k	$88.00 k	NEW
Townsquare Capital	14.45 k	$86.00 k	0.0%
Schonfeld Strategic Advisors	14.10 k	$83.00 k	-92.5%
NTRS Northern Trust	10.62 k	$63.00 k	NEW
Advisor	2.00 k	$12.00 k	NEW
MS Morgan Stanley	1.30 k	$8.00 k	-3.7%
Tower Research Capital	631.00	$4.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Donald M Soffer	0.00	-77.73 mm	EXIT
Schonfeld Strategic Advisors	14.10 k	-174.31 k	-92.5%
Sassicaia Capital Advisers	0.00	-102.00 k	EXIT
C Citigroup	0.00	-72.78 k	EXIT
Vanguard	173.67 k	+57.80 k	+49.9%
Gamco Investors	0.00	-32.50 k	EXIT
BLK Blackrock	110.00 k	+27.01 k	+32.5%
Anson Funds Management	0.00	-20.00 k	EXIT
Alps Advisors	0.00	-19.66 k	EXIT
STT State Street	14.80 k	+14.80 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LGVN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 23	Joshua Hare	Common Stock	Sell	Dispose S	No	Yes	4.28	20,000	85.60 k	7,793,263
3 Jan 23	Paul T Lehr	Common Stock	Payment of exercise	Dispose F	No	No	3.37	1,472	4.96 k	147,042
3 Jan 23	James Clavijo	Common Stock	Payment of exercise	Dispose F	No	No	3.37	1,288	4.34 k	75,649
21 Dec 22	Erin Borger	Stock Option Common Stock	Grant	Acquire A	No	No	3	5,000	15.00 k	5,000
11 Nov 22	James Clavijo	Common Stock	Gift	Dispose G	No	No	0	5,000	0.00	70,649